1. FDA review for Uroxatral (alfuzocin HCL tablets);Anon,2003
2. ICH S7B: The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals;Anon,2005
3. ICH E14: The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs;Anon,2005
4. Bass, A. S., Darpo, B., Breidenbach, A., Bruse, K., Feldman, H., Garnes, D., et al. (in preparation). Workshop: Moving towards better predictors of drug-induced torsade de pointe.
5. QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: etiology and interventions;Carlsson;Journal of Cardiovascular Pharmacology,1990